Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies

Immunobiology

Volumn 210, Issue 9, 2005, Pages 639-645

  Zhang, Geng ^a   Lu, Hong ^b   Lu, Yun ^a   Jiang, ShiBo ^b   Chen, Ying Hua ^a  

^a TSINGHUA UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

Epitope; HIV 1; Monoclonal antibody; Neutralization

Indexed keywords

EPITOPE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTIGENICITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SPLEEN CELL; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 27744441119     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2005.05.025     Document Type: Article

References (23)

1. Y.H. Chen Y. Xiao T. Yu M.P. Dierich Epitope-vaccine: A new strategy against HIV-1 Immunol. Today 20 1999 588-589
2. T.C. Chou P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27-55
3. E. Coeffier J.M. Clement V. Cussac N. Khodaei-Boorane M. Jehanno M. Rojas Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein Vaccine 19 2000 684-693
4. A.J. Conley J.A. Kessler J.S. Tung B.A. Arnold P.M. Keller E.A. Emini Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41±2F5, an anti-gp41 human monoclonal antibody Proc. Natl. Acad. Sci. USA 91 1994 3348-3352
5. M.P. D'Souza S.J. Geyer C.V. Hanson R.M. Hendry G. Milman Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: An international collaboration AIDS 8 1994 169-181
6. L. Eckhart W. Raffelsberger B. Ferko A. Klima M. Purtscher H. Katinger Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus J. Gen. Virol. 77 1996 2001-2008
7. T. Fouts K. Godfrey K. Bobb R. Pal Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques Proc. Natl. Acad. Sci. USA 99 2002 11842-11847
8. J. Ho R.A. Uger M.B. Zwick M.A. Luscher B.H. Barber K.S. Macdonald Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response Vaccine 23 2005 1559-1573
9. X. Liang S. Munshi J. Shendure Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein Vaccine 17 1999 2862-2872
10. Z.Q. Liu Y.H. Chen Design and construction of a recombinant epitope - peptide gene as a universal epitope-vaccine strategy J. Immunol. Methods 285 2004 93-97
11. Z.Q. Liu Z.G. Wang Y.H. Chen Predefined spacers between epitopes on a recombinant epitope-peptide impacted epitope-specific antibody response Immunol. Lett. 97 2005 41-45
12. J.R. Mascola G. Stiegler T.C. VanCott H. Katinger C.B. Carpenter C.E. Hanson Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies Nat. Med. 6 2000 207-210
13. T. Muster F. Steindl M. Purtscher A. Trkola A. Klima G. Himmler H. Katinger A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 J. Virol. 67 1993 6642-6647
14. T. Muster R. Guinea A. Trkola M. Purtscher A. Klima H. Katinger Cross-neutralizing antibodies against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS J. Virol. 68 1994 4031-4034
15. M. Purtscher A. Trkola G. Gruber A. Buchacher R. Predl F. Steindl C. Tauer R. Berger N. Barrett A. Jungbauer H. Katinger A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1 AIDS Res. Hum. Retroviruses 10 1994 1651-1657
16. M. Purtscher A. Trkola A. Grassauer Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 AIDS 10 1996 587-593
17. E.O. Saphire P.W. Parren R. Pantophlet Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design Science 293 2001 1155-1159
18. G. Stiegler R. Kunert M. Purtscher A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1 AIDS Res. Hum. Retroviruses 17 2001 1757-1765
19. A. Trkola A.B. Pomales H. Yuan B. Korber P.J. Maddon G.P. Allaway H. Katinger D.R. Burton Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG J. Virol. 69 1995 6609-6617
20. C.D. Weiss J.M. White Characterization of stable of Chinese hamster ovary cells expressing wild-type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein J. Virol. 67 1993 7060-7066
21. H. Zhang Y. Huang R. Fayad G.T. Spear L. Qiao Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles J. Virol. 78 2004 8342-8348
22. S. Zolla-Pazner Identifying epitopes of HIV-1 that induce protective antibodies Nat. Rev. Immunol. 4 2004 199-210
23. M.B. Zwick H.K. Komori R.L. Stanfield S. Church M. Wang P.W. Parren D.R. Burton The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5 J. Virol. 78 2004 3155-3161